Lytix Biopharma Q3 2026 loss widens 12% year on year to NOK 26.1 million

• Lytix Biopharma’s third-quarter 2026 loss widened 12% year over year to NOK 26.1 million.
• Operating expenses rose 15% year over year to NOK 27.9 million.
• Cash and short-term financial investments fell 26% from June 30 to NOK 67.3 million at September 30, 2026.
• NeoLIPA met its primary endpoint in neoadjuvant melanoma, achieving the prespecified pathological complete response threshold of at least 40%.
• Phase III preparations are underway; FDA feedback indicated one well-designed trial may support a US approval application, depending on overall results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 20261113:BIT:8687:0) on November 13, 2026, and is solely responsible for the information contained therein.